10%; DL,CO >15%) or "marginal" (FVC 5-10%; DL,CO 7.5-15%). Proportional hazards analysis and time-dependent receiver operating characteristic methodology were used to examine PFT trends against mortality. In IPF, reductions in FVC were significant in 22 cases (26%) and marginal in 19 cases (23%). Mortality was higher in patients with a significant decline in FVC (hazard ratio (HR) 2.80, 95% CI 1.54-5.06; p<0.001) and those with a marginal decline in FVC (HR 2.31, 95% CI 1.19-4.50; p = 0.01) than in those with stable disease. Progression-free survival was lower when the decline in FVC was marginal than in stable disease (HR 2.34, 95% CI 1.19-4.60; p = 0.01). Marginal changes in DL,CO in IPF and marginal changes in FVC and DL,CO in fibrotic NSIP did not provide useful prognostic information. Marginal change in FVC in IPF denotes a poor outcome. These findings are applicable to clinical practice and to the selection of patients with more progressive disease for therapeutic studies.">

Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis

Zappala C. J., Latsi P. I., Nicholson A. G., Colby T. V., Cramer D., Renzoni E. A., Hansell D. M., du Bois R. M., Wells A. U.

Source: Eur Respir J 2010; 35: 830-836
Journal Issue: April
Disease area: Interstitial lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Zappala C. J., Latsi P. I., Nicholson A. G., Colby T. V., Cramer D., Renzoni E. A., Hansell D. M., du Bois R. M., Wells A. U.. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830-836

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Early decrease of forced vital capacity is a good prediction tool for prognosis in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Year: 2008

Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J, 52 (2) 1702593; 10.1183/13993003.02593-2017
Year: 2018



Spirometric evaluation of idiopathic pulmonary fibrosis (IPF): forced or slow vital capacity?
Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia
Year: 2019


Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
Source: Eur Respir Rev 2012; 21: 161-167
Year: 2012



Forced vital capacity decreases rapidly in patients with idiopathic upper lobe-dominant pulmonary fibrosis
Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases
Year: 2011


Does rapid decline predict poor prognosis?
Source: Annual Congress 2007 - Rapid decline in lung function and its consequences
Year: 2007


Forced vital capacity, total lung capacity and diffusion capacity in idiopathic pulmonary fibrosis
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018




Coexistent pulmonary emphysema delays the decrease in vital capacity in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease
Year: 2008


Forced vital capacity (FVC) decline in idiopathic pulmonary fibrosis (IPF) – modelling the myth
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019


The impact of low forced vital capacity on comorbidities and behavior restriction in chronic obstructive pulmonary disease
Source: International Congress 2018 – Patient-reported outcomes and scores in COPD
Year: 2018


Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015

Challenges in idiopathic pulmonary fibrosis trials: the point on end-points
Source: Eur Respir Rev 2011; 20: 195-200
Year: 2011



Diaphragm dysfunction in combination with lung function decline is associated with higher mortality in idiopathic pulmonary fibrosis patients
Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias
Year: 2018

Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients?
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017

Impaired pulmonary function and its association with clinical outcomes, exercise capacity and quality of life in children with congenital heart disease
Source: Virtual Congress 2020 – Clinical year in review
Year: 2020

Glycaemic variability indices are associated with increased pulmonary function decline in people with cystic fibrosis
Source: International Congress 2018 – Cystic fibrosis: diagnosis and monitoring
Year: 2018


Posture-induced changes in vital capacity are associated with COPD outcomes independent of airflow obstruction in SPIROMICS
Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases
Year: 2021


Twenty-four week decline in forced vital capacity predicts mortality at week 52 in the INPULSIS® trials
Source: International Congress 2016 – IPF treatment I
Year: 2016



Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis
Source: Eur Respir J 2012; 40: 61-66
Year: 2012



Evaluation of annual FEV1 decline and factors associated with its accelerated deterioration in a cohort of adults with cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013